AMCP Biosimilars Operational Readiness Initiative
Biosimilars are gaining some traction in the US marketplace after a slow start; however, there are persistent and complex barriers to evaluation and adoption. AMCP members indicate that "operational readiness" tools are needed to help managed care organizations assess the readiness of biosimilar adoption. AMCP will convene a panel of experts from the managed care, pharmacy benefit, and integrated delivery networks to identify their needs and define specific resources to aid in assessing and implementing biosimilars when formulary coverage is approved.
This advisory group will launch in Q4 of 2022 — more information to come.